Insider Cluster (2 insiders) ·Filed Jul 15, 2026

ONC

BeOne Medicines Ltd.
BEARISH
Impact 5/10
Horizonweeks Processed2mo ago
Insider cluster: 2 insiders, $1.5M total
Actionable Insight ▼ Bearish

Monitor for further insider selling or any negative corporate news. While the stock has shown resilience after prior neutral reports, large CEO sales often precede periods of underperformance. Watch next 10-Q for any fundamental deterioration.

DirectionBearish
Confidencemedium
Horizonweeks
Latest settled — T+20d
ONC ▲ +15.35% at T+20d
SHORT call ✗ call lost -15.35% · α vs SPY -13.01% · entry $311.26 → $359.05
Next anchor: T+60d in 5d
Latest observation: T+53 -25.40% FF3 residual α
Entry anchored
Jul 14, 03:59 PM ET
via exchange tick
T+1d
+1.98%
call -1.98% · α -2.52%
$317.42
settled 3mo ago
T+5d
+2.79%
call -2.79% · α -3.77%
$319.93
settled 2mo ago
T+20d
+15.35%
call -15.35% · α -13.01%
$359.05
settled 7w ago
T+60d
—
call — · α —
—
in 5d

Price Chart

Loading chart...

Executive Summary

BeOne Medicines CEO John Oyler sold 4,139 shares and General Counsel Lee Chan Henry sold 664 shares, totaling $1.46M in this filing. However, broader Form 4 filings over the past week reveal Oyler sold over $47M in stock (~0.14% of market cap), a notable insider selling cluster. While insider sales are less predictive than buys, the magnitude and executive-level concentration warrant caution.

Key Financial Metrics

Direction
selling
Total Value
$1.5M
Insiders
2

Key Facts

  • CEO John Oyler sold 4,139 shares at $303.07 in this filing
  • General Counsel Lee Chan Henry sold 664 shares at $302.46
  • Total reported sell value: $1.46M (0.004% of market cap)
  • Cross-filing context shows Oyler sold >$47M in open-market sales over July 10-14, 2026
  • Market cap: $33.8B; analyst consensus 92% bullish

Financial Impact

CEO selling of ~$47M represents 0.14% of $33.8B market cap, modest but notable for a single insider

insider sellingCEO ownership stake

Risk Factors

  • CEO selling may be for tax or diversification, not a signal of distress
  • Historical insider sales are weak predictors on average
  • Stock has strong analyst support (92% bullish) which could offset bearish sentiment

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-ONC-1784080888763
19 reports for ONC
Performance horizon
75% Hit rate 3 of 4 directional calls best @ T+20▲ +10.46%Aug 5, 2026
Filters
Rows
Reports for ONC — sortable, filterable
TypeNow
Sep 10, 2026
22d ago
Insider Cluster
NEUTRAL ★ 3/10
$346.51 $350.84▲ +1.25%▲ +1.47%$358.07 (+3.34%)
Sep 3, 2026
29d ago
Insider Cluster
NEUTRAL ★ 2/10
$362.68 $346.51▼ −4.46%▼ −3.31%$358.07 (−1.27%)
Aug 26, 2026
5w ago
8-K
NEUTRAL ★ 2/10
$375.80 $361.78▼ −3.73%▼ −3.61%$358.07 (−4.72%)
Aug 14, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$347.48 $374.47▲ +7.77%▲ +9.14%$358.07 (+3.05%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$356.01 $369.16▲ +3.69%▲ +5.66%$358.07 (+0.58%)
Aug 10, 2026
7w ago
144
BEARISH ★ 6/10
$359.27 $369.15▼ −2.75%▼ −3.15%$358.07 (+0.33%)
Aug 5, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$329.80 $356.01▲ +7.95%▲ +6.73%$358.07 (+8.57%)
Aug 5, 2026
8w ago
8-K
BULLISH ★ 7/10
$327.53 $359.05▲ +9.62%▲ +9.27%$358.07 (+9.32%)
Jul 24, 2026
10w ago
Insider Cluster
NEUTRAL ★ 2/10
$325.90 $322.08▼ −1.17%▼ −1.55%$358.07 (+9.87%)
Jul 17, 2026
11w ago
Insider Cluster
BEARISH ★ 5/10
$312.02 $326.77▼ −4.73%▼ −5.41%$358.07 (−14.76%)
Showing 10 of 19

US Market Status

Market Closed — Opens Mon (64h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Jul 15, 2026